JP2022521663A - 抗-tm4sf4抗体及びこの用途 - Google Patents
抗-tm4sf4抗体及びこの用途 Download PDFInfo
- Publication number
- JP2022521663A JP2022521663A JP2021542571A JP2021542571A JP2022521663A JP 2022521663 A JP2022521663 A JP 2022521663A JP 2021542571 A JP2021542571 A JP 2021542571A JP 2021542571 A JP2021542571 A JP 2021542571A JP 2022521663 A JP2022521663 A JP 2022521663A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- antigen
- tm4sf4
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 168
- 239000000427 antigen Substances 0.000 claims abstract description 168
- 108091007433 antigens Proteins 0.000 claims abstract description 167
- 102000036639 antigens Human genes 0.000 claims abstract description 167
- 201000011510 cancer Diseases 0.000 claims abstract description 162
- 101000658581 Homo sapiens Transmembrane 4 L6 family member 4 Proteins 0.000 claims abstract description 101
- 102100034897 Transmembrane 4 L6 family member 4 Human genes 0.000 claims abstract description 97
- 230000027455 binding Effects 0.000 claims abstract description 92
- 239000012634 fragment Substances 0.000 claims abstract description 72
- 210000000130 stem cell Anatomy 0.000 claims abstract description 64
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 238000011394 anticancer treatment Methods 0.000 claims abstract description 18
- 230000010261 cell growth Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 197
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 30
- 230000005855 radiation Effects 0.000 claims description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000018212 fibroblastic neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000010837 poor prognosis Methods 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 66
- 239000013598 vector Substances 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 42
- 239000000243 solution Substances 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000001764 infiltration Methods 0.000 description 14
- 230000008595 infiltration Effects 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 230000009257 reactivity Effects 0.000 description 13
- 230000005012 migration Effects 0.000 description 12
- 238000013508 migration Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 10
- 239000006143 cell culture medium Substances 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 description 7
- 101710196131 Aldehyde dehydrogenase 1 Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- -1 cavenicillin Chemical compound 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100040069 Aldehyde dehydrogenase 1A1 Human genes 0.000 description 3
- 102100039075 Aldehyde dehydrogenase family 1 member A3 Human genes 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000890570 Homo sapiens Aldehyde dehydrogenase 1A1 Proteins 0.000 description 3
- 101000959046 Homo sapiens Aldehyde dehydrogenase family 1 member A3 Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 206010064912 Malignant transformation Diseases 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000005880 cancer cell killing Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000008863 intramolecular interaction Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000036212 malign transformation Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 108700031126 Tetraspanins Proteins 0.000 description 2
- 102000043977 Tetraspanins Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000050357 human TM4SF4 Human genes 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012482 interaction analysis Methods 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000658574 Homo sapiens Transmembrane 4 L6 family member 1 Proteins 0.000 description 1
- 101000658584 Homo sapiens Transmembrane 4 L6 family member 5 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000191965 Staphylococcus carnosus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 1
- 102100034898 Transmembrane 4 L6 family member 5 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 108010029257 guanosine-diphosphatase Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Member 4)に特異的に結合する抗体又はその抗原結合断片、及びこれを含む癌の予防又は治療用組成物に関する。
al.,Oncotarget.2017;8(60):101284-101297)。
分子を含む発現ベクター、前記発現ベクターを含む宿主細胞、前記宿主細胞を培養する段階を含む、抗体又はこの抗原結合断片の生産方法を提供することにある。
本発明の他の一側面は、前記抗体又はこの抗原結合断片を暗号化する核酸分子を提供する。
本発明のまた他の一側面は、前記核酸分子を含む発現ベクターを提供する。
本発明のまた他の一側面は、前記発現ベクターを含む宿主細胞を提供する。
本発明のまた他の一側面は、前記宿主細胞を培養する段階を含む、抗体又はこの抗原結合断片を生産する方法を提供する。
本発明のまた他の一側面は、前記抗体又はこの抗原結合断片を含むTM4SF4検出用組成物及びキットを提供する。
本発明のまた他の一側面は、癌幹細胞成長抑制用組成物を提供する。
本発明のまた他の一側面は、抗体又はこの抗原結合断片を含む放射線抗癌治療補助用組成物を提供する。
したがって、本発明の新規の抗体又はこの抗原結合断片は、TM4SF4を標的とする新たな抗体医薬品の開発に有用に用いられ得る。
一側面において、本発明は、
TM4SF4(TransMembrane 4 Superfamily Member 4)に特異的に結合する抗体又はこの抗原結合断片を提供する。
region)を有するという点でFabと差がある。F(ab’)2抗体は、Fab’のヒンジ領域のシステイン残基がジスルフィド結合をなしながら生成される。Fvは、重鎖の可変領域及び軽鎖の可変領域のみを有している最小の抗体片を意味する。二重鎖Fv(two-chain Fv)は、非共有結合で重鎖の可変領域と軽鎖の可変領域が連結されており、単鎖Fv(single-chain Fv)は、一般的にペプチドリンカーを介して重鎖の可変領域と単鎖の可変領域が共有結合で連結さるか又はC-末端でそのまま連結されているので、二重鎖Fvのようにダイマーのような構造をなすことができる。これに制限されるものではないが、このような抗体断片は、タンパク質加水分解酵素
を用いて得られ[例えば、全体抗体をパパインで制限切断すれば、Fabを得ることができ、ペプシンで切断すれば、F(ab’)2断片を得ることができる]、又は遺伝子組み換え技術を介して製作することができる。
る用語「軽鎖」は、抗原に特異性を付与するための十分な可変領域配列を有するアミノ酸配列を含む可変領域ドメインVL及び不変領域ドメインCLを含む全長軽鎖及びこの断片をいずれも含んでよい。
R-L3を含む軽鎖の可変領域を含む抗体と同一のエピトープに結合する変異体抗体をいう。通常の技術者は、特定された軽鎖及び重鎖CDR配列に基づき、公知の技術を用いて前記親和度最適化抗体を製造することができる。
機能的な結合を意味し、これにより前記調節配列は、前記他の核酸配列の転写及び/又は解読を調節するようになる。
本発明の組み換えベクターシステムは、当業界に公知の多様な方法を介して構築され得る。
99-445)が調節部位として用いられ得る。宿主細胞としてバチルス菌が用いられる場合、バチルスチューリンゲンシスの毒素タンパク質遺伝子のプロモーター(Appl Environ Microbiol(1998)64:3932-3938;Mol Gen Genet(1996)250:734-741)、又はバチルス菌で発現可能な如何なるプロモーターでも調節部位に用いられ得る。
なので、精製のための更なる配列がなくとも、発現された抗体は、タンパク質Aカラムなどを介して容易に精製することができる。
ansfomation)又は標的形質転換(targeted transformation)を介して宿主細胞に導入され得る。同時形質転換は、軽鎖及び重鎖をコーディングするそれぞれのベクターDNAを同時に宿主細胞に導入した後、軽鎖と重鎖を全て発現する細胞を選別する方法である。標的形質転換は、軽鎖(又は重鎖)を含むベクターに形質転換された細胞を選別し、選別された細胞を、重鎖(又は軽鎖)を含むベクターに再び形質転換して軽鎖及び重鎖の全てを発現する細胞を最終的に選別する方法である。
また他の側面において、本発明は、前記抗体又はこの抗原結合断片を含む、癌の予防又は治療用組成物を提供する。
前記抗体及びこの抗原結合断片は、先に説明したとおりである。
前記組成物は、薬学的組成物、医薬外品組成物、健康食品用組成物の形態であってよい
。
また、本発明は、前記抗体又はこの抗原結合断片を含む、癌幹細胞成長抑制用組成物を提供する。
また他の側面において、本発明は、前記抗体又はこの抗原結合断片を有効成分として含む放射線抗癌治療補助用組成物を提供する。
但し、下記実施例及び実験例は本発明を具体的に例示するものであり、本発明の内容が下記実施例及び実験例によって限定されはしない。
TM4SF4-抗原に対するヒト単一クローン抗体の生成
<1-1> ヒトTM4SF4膜タンパク質抗原特異抗体の製造のためのエピトープ配列の選別
TM4SF4抗原が媒介する癌幹細胞特性関連の信号伝達体系を抑制することができるTM4SF4特異反応抗体を製造するため、202個のアミノ酸からなる膜タンパク質であるTM4SF4抗原構造から細胞外に露出され、抗体誘導能が高いものと予想される部位を選別しようとした。
選定した抗原配列のペプチドのアミノ末端にシステインを付加した配列のペプチド「CTWGYPFHDGDYLN DE」を合成し、Sulfo-SMCCを用いてBSA(Bovine serum albumin)にコンジュゲーションした。準備された抗原は、マウス4匹に一般的な免疫化過程により3回注射し、免疫化の効果で血液中に抗原特異反応抗体が増加したか否かをELISAで確認した。最終免疫化後に抗体の生成が確認されたマウスの脾臓細胞(splenocyte)を採取し、マウスのミエローマ(myeloma)細胞と融合して抗体生成B細胞ハイブリドーマ細胞を確保した。融合細胞株の培養にHAT選別培地を用いて成功的に融合されたB細胞ハイブリドーマを多数確保し、ハイブリドーマ細胞選別の一般的なプロトコールにより培養しながら、細胞培養液中で抗原特異抗体をELISA法で検査した。ELISAには、免疫化に用いていた抗原ペプチドコンジュゲートBSAと、対照群としてBSAとをコーティング抗原(100ng/well)として用いた。
新規抗体のin vitro/vivo効能の検証のために、ECL-2B7などのB細胞ハイブリドーマクローンを大量培養し、培養液から抗体を精製した。
ドフォード(Bradford)法及びELISA法で定量し、SDS-PAGEで純度を確認した。
新規の抗-TM4SF4抗体の抗原特異反応性の確認
<2-1> 酵素結合免疫吸着検査法(Enzyme-Linked Immunosorbent Assay:ELISA)による新規抗体の抗原特異反応の検証
ce、SPR)による新規抗体の分子間相互作用の検証
新規抗体の抗原特異反応性を確認するため、実施例2-1で用いたTM4SF4-peptide-BSA(Biotin-GSAGGSTWGYPFHDGDYLNDE)を抗原として用い、ECL-2B7、ECL-4C1及びECL-12A8抗体を処理して測定した。
これを介し、ECL-2B7、ECL-4C1及びECL-12A8抗体がペプチド抗原に対して結合能力が大きい抗体であることが分かる。
LAG-TM4SF4タンパク質の発現を誘導し、免疫沈降法とウェスタンブロッティングで新規抗体に対する特異反応性を検証した。遺伝子伝達感染した細胞を、RIPAバッファー(1% NP40、0.5% Sodium deoxycholate、0.1% SDS、phosphatase inhibitors、pretease inhibitors/PBS)に溶かし、21振幅で5秒間音波破砕した後、4℃で13,000rpmで遠心分離して細胞タンパク質溶液を得た。ブラッドフォード(Bradford)法でタンパク質定量を実施し、500μgのタンパク質を5μgの新規抗体又は対照群抗体であるマウス抗-GAPDH抗体と4℃で16時間混合し、抗体とタンパク質の抗原/抗体の結合を誘導し、30μlのProtein Gビーズを追加して再び4時間反応させることにより抗体をビーズに結合させた。非特異タンパク質を除去するため、ビーズをRIPAバッファーで6回洗浄した後、還元剤が含まれたSDSサンプルバッファーを添加して95℃で沸騰し、12%SDS-PAGEゲルでタンパク質を展開した。展開されたタンパク質はPVDF膜(membrane)に移動させ、タンパク質移動の完了した膜は、5%(w/v)脱脂乳を含んだTBST(Tris-buffered saline、0.1% Tween 20)ブロッキング溶液で室温で1時間ブロッキ
ング(blocking)し、ブロッキング溶液に希釈した抗-FLAG抗体(Cell
signaling technology)を室温で2時間処理した後、TBSTで5分間8回撹拌し洗浄して非特異抗体を除去した。3xFLAG-TM4SF4タンパク質に結合された抗-FLAG抗体は、二次抗体(ウサギ抗-IgG-HRP)を処理した後、ECL(enhanced chemiluminescence)方法で検出した。
新規抗体が細胞面発現TM4SF4を特異的に認識することができるのか確認するため
、細胞面発現TM4SF4に対する結合能を免疫蛍光法(Immunofluorescence analysis)で検証した。
cca ggg aac cac auu gag agg c-3’(配列番号31)]又は対照群Stealth RNAiTMNegative Control Medium GC(Invitrogen)をLipofectamine(登録商標)RNAiMAXreagent(Invitrogen)を用いてA549細胞内に転移させ、48時間後に収去して1×105個の細胞をカバーグラスが準備されたディッシュに24時間培養した。培養された細胞の培養液を除去した後、前述したとおり、パラホルムアルデヒド溶液で細胞を固定して新規抗体を反応させた。抗原と結合された抗体は、ブロ
ッキング溶液に1:1000の比率に希釈されたマウス抗-IgG-FITC二次抗体を1時間処理し、洗浄溶液を再び5分間3回処理した後、DAPI溶液で5分間細胞核を染色して蛍光顕微鏡で確認した。
抗-TM4SF4抗体による癌幹細胞の成長抑制効果の確認
TM4SF4抗原反応特異性が確認された新規抗体の癌幹細胞特性抑制の効果を確認するため、Sphere forming assay、そして、Invasion及びMigration assayを実施した。
<3-1> 癌幹細胞の分離及び培養
A549-ALDH1+癌幹細胞をDMEM-F12(Invitrogen)、epidermal growth factor(EGF:20ng/mL)、basic
fibroblast growth factor(20ng/mL)及び2%のB27 serum-free supplement(1:50)を含む癌幹細胞許容培地に培養した。細胞培養器としては、ultra-low attachment 96-well plate(コーニング社製)を用いた。培養器ウェル当り1~2個の細胞を添加し、24時間安定化させた後、細胞培養液に新規抗体又はシグマ社製の抗-TM4SF4抗体を3μg/mlの濃度でそれぞれ処理した。処理後、37℃の加湿された5%のCO2細胞培養器で培養を行い、10日後、癌幹細胞を対象に顕微鏡を用いて球状形成の個数及び大きさを確認した。
A549細胞(5x104cells/well)を、0.2mlの無血清RPMI培地に懸濁した。浸潤分析のためには、マトリゲル(Matrigel)10mg/mlにプレコーティングされた8μmのポアサイズのトランスウェルチャンバ(Transwell chamber)の上部ウェル(Upper well)に細胞を分株した。準備した上部ウェルは、0.8mlの血清含有RPMI培地で満たされた下部ウェルチャンバの上にかけておいて培養し、37℃で48時間培養後、上部フィルターの外側に移動した浸湿細胞を染色して分析した。移動分析時には、浸潤実験時に用いたインサート(Insert)にマトリゲルがコーティングされていないチャンバを用いた。抗体は、上部ウェルに3μg/mLの濃度で細胞分株と同時に添加した。
これにより、本発明の新規抗体が癌細胞の浸潤能及び移動能を効果的に抑制できることが分かる。
抗-TM4SF4抗体による癌細胞の放射線に対する抵抗力抑制効果の確認
A549細胞及びHuh7細胞を、それぞれ35mmのディッシュに1×103cells/dishで塗布した。24時間後、細胞培養液に新規抗体(ECL-2B7、ECL-4C1、ECL-12A8)又はシグマ社製の抗-TM4SF4抗体を3μg/mlの濃度でそれぞれ処理した。処理後、7日間、37℃の加湿された5%のCO2細胞培養器で培養した。培養液を除去したプレートに0.5%のクリスタルバイオレット試薬で10分間染色した後、数回PBSで洗浄して顕微鏡で確認した。放射線照射の敏感性を確認するためには、A549細胞に60Co γ-ray源を用いて総放射線量6Gy(線量率(dose rate):x/時間)を照射してプレートに塗布した後、24時間後に抗体を処理した。
抗-TM4SF4抗体の癌細胞死滅誘導に関する細胞内信号伝達過程の確認
本発明の新規抗体の癌細胞死滅誘導に関与する細胞内信号伝達過程を検証するため、TM4SF4関連の信号伝達過程を確認し、抗体によりこれらが影響を受けるのかを調べた。
sis)溶液を50μlずつ入れ、4℃で30分間反応した後、13000RPMの4℃の遠心分離機でペレットと上澄み液を分離した。前記上澄み液をタンパク質定量キット(sigma)を用いてそれぞれのタンパク質を40μgずつSDS-PAGEゲルにローディングした。その後、SDS-PAGEゲルにローディングされたタンパク質をニトロセルロースメンブレンに移動させた後、BSAバッファーで30分常温で反応させて他の抗体が結合できないようにしてから、一次抗体TM4SF4、ALDH1A1、ALDH1A3(Abcam)、β-catenin、CD133、Oct4(millipore)とCD44、β-actin(cell signaling)を1:1000に希釈したPBSバッファーに4時間反応した後、再び二次抗体抗-Rabbit又は抗-Mouse Igs-HRP(cell signaling)を1:10000に希釈したPBSバッファーに1時間反応させた。その後、PBSで5回ニトロセルロースメンブレンを洗浄してからECL検出溶液で反応した後、フィルムに感光させた。
新規抗体の癌細胞死滅効能の確認のためのマウスのゼノグラフトアッセイ(Xenograft assay)
新規抗体の癌細胞死滅の効能を生体条件で確認するため、マウスに肺癌細胞ゼノグラフト(xenograft)を形成させて新規抗体を注入し、癌細胞成長の抑制/又は死滅の可否を検証した。
果、前記で実験した実験と類似の結果を得ることができた(図11のE、F)。
新規の単一クローン抗体ECL-2B7とECL-4C1の抗体遺伝子のクローニング及び塩基配列の分析
新規抗体の抗原に対する相補性決定領域(CDR)を決定することで抗体特異性の究明を図った。新規抗体のCDR部位に該当するタンパク質配列を決定する抗体遺伝子をクローニングし、CDR部位の塩基配列を決定した。
233:167)。合成されたcDNAで重鎖(heavy chain)クローニングするためには、IgG1亜型抗体であるECL-2B7及びIgG2a亜型抗体であるECL-4C1の各々の不変領域に該当する重合酵素連鎖反応プライマーである塩基配列5’-GGA GTC GAC ATA GAC AGA TGG GGG TGT CGT TTT GGC-3’(IgG1亜型不変領域)又は5’-GGA GTC GAC CTT GAC CAG GCA TCC TAG AGT CA-3’(IgG2a亜型不変領域)であるオリゴヌクレオチド10pmoleと、重鎖抗体可変領域のN末端に該当するプライマーである塩基配列5’MH1 5’-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TC-3’と5’MH2-5’-ctt ccg gaa ttc SAR GTN MAG CTG SAG SAG TCW GG-3’であるオリゴヌクレオチドとを入れて連鎖重合反応混合液を作製した。軽鎖(light chain)クローニングのためには、カッパ鎖(kappa
chain)不変領域に該当するプライマーである5’-ggt gtc gac GGA TAC AGT TGG TGC AGC ATC-3’オリゴヌクレオチドと、カッパ鎖可変領域のN末端に該当するプライマーである5’MK 5’-cgg aag
ctt GAY ATT GTG MTS ACM CAR WCT MCA-3’とをそれぞれ用いた。重合酵素連鎖反応産物の効率的なクローニングのために、軽鎖の場合は、3’-プライマーの末端にSalI制限酵素のサイトを付与し、5’-プライマーの場合、HindIII制限酵素のサイトを付与した。重鎖の場合には、5’-プライマーにはEcoRI、3’-プライマーにはSalI制限酵素のサイトを付与した。重鎖及び軽鎖反応液をそれぞれ交ぜた後、先ず95℃で1分、40℃で1分、72℃で1分で30回反応させた。増幅し出したECL-2B7とECL-4C1遺伝子をクローニングするため、先ず、重合酵素連鎖反応産物を、重鎖はEcoRIとSalIで処理し、軽鎖はHindIIIとSalIで処理した後、1.0%(w/v)アガロースゲルに展開させてFavorPrep GELTMPCR Purification Kit(Favorgen社製、台湾)で約400bpと390bpに該当するDNAを分離した。重鎖遺伝子をクローニングするベクターとして用いるpBluescript KS+をEcoRIとSalIで処理し、軽鎖遺伝子のクローニングベクターとしては、pBluescript KS+をHindIIIとSalIで処理した後、FavorPrep GELTMPCR Purification Kitで分離した(図12のC、D)。この2つのDNAをT4 DNA連結酵素(New England Biolab社製、米国)で連結し、大腸菌DH5αにCaCl2方法で形質転換した。重鎖の場合、約400
bpサイズのDNA挿入物を有したクローン、軽鎖の場合、約390bpのサイズを有した大腸菌クローンを選抜した。
群集形成能力の比較による他の癌腫への拡張性の検証
新規抗体の多様な癌細胞悪性化抑制の程度を確認するため、細胞の群集能力の比較実験を進めた。
具体的に、Colony forming assayのために肺癌細胞であるH1299と肝癌細胞であるHuh7細胞、乳癌細胞であるMCF7とMDA-MB 231細胞、及び膵臓癌細胞であるMIA-Paca-2細胞を35mmのディッシュに1×103cells/dishで塗布した。24時間後、細胞培養液に新規抗体(ECL-2B7)を5μg/mlの濃度でそれぞれ処理した。処理後、7日間、37℃の加湿された5%のCO2細胞培養器で培養した。培養液を除去したプレートに0.5%のクリスタルバイオレット試薬で10分間染色後、数回PBSで洗浄し、顕微鏡で確認した。
これを介し、新規抗体のTM4SF4抗原特異結合を用いて多様な癌を対象とした抗癌治療技術を提案できることが分かる。
Claims (18)
- TM4SF4(TransMembrane 4 Superfamily Member 4)に特異的に結合する抗体又はこの抗原結合断片であって、
前記抗体は、配列番号2のアミノ酸配列を含むエピトープ領域に結合するものである、抗体又はこの抗原結合断片。 - 前記抗体は、
(a)配列番号3のアミノ酸配列を含むCDR-H1、配列番号4のアミノ酸配列を含むCDR-H2、配列番号5のアミノ酸配列を含むCDR-H3を含む重鎖の可変領域;及び配列番号6のアミノ酸配列を含むCDR-L1、配列番号7のアミノ酸配列を含むCDR-L2、及び配列番号8のアミノ酸配列を含むCDR-L3を含む軽鎖の可変領域を含む抗体;又は、
(b)配列番号9のアミノ酸配列を含むCDR-H1、配列番号10のアミノ酸配列を含むCDR-H2、配列番号11のアミノ酸配列を含むCDR-H3を含む重鎖の可変領域;及び配列番号12のアミノ酸配列を含むCDR-L1、配列番号13のアミノ酸配列を含むCDR-L2、配列番号14のアミノ酸配列を含むCDR-L3を含む軽鎖の可変領域を含む抗体である、請求項1に記載の抗体又はこの抗原結合断片。 - 前記抗体は、
配列番号15のアミノ酸配列を含む重鎖の可変領域;及び配列番号16のアミノ酸配列を含む軽鎖の可変領域を含むものである、請求項2に記載の抗体又はこの抗原結合断片。 - 前記抗体は、
配列番号19のアミノ酸配列を含む重鎖の可変領域;及び配列番号20のアミノ酸配列を含む軽鎖の可変領域を含むものである、請求項2に記載の抗体又はこの抗原結合断片。 - 前記抗原結合断片は、Fab、F(ab’)、F(ab’)2又はFvであるものである、請求項1から4の何れか一項に記載の抗体又はこの抗原結合断片。
- 請求項1から4の何れか一項に記載の抗体又はこの抗原結合断片を暗号化する核酸分子。
- 請求項6に記載の核酸分子を含む、発現ベクター。
- 請求項7に記載の発現ベクターを含む、宿主細胞。
- 請求項8に記載の宿主細胞を培養する段階を含む、抗体又はこの抗原結合断片を生産する方法。
- 請求項1から4の何れか一項に記載の抗体又はこの抗原結合断片を含む、TM4SF4検出用組成物。
- 請求項10に記載のTM4SF4検出用組成物を含む、TM4SF4検出用キット。
- 請求項1から4の何れか一項に記載の抗体又はこの抗原結合断片を、TM4SF4抗原を含むものと予想される検出対象試料と接触させる段階を含む、TM4SF4抗原を検出する方法。
- (a)請求項1から4の何れか一項に記載の抗体又はこの抗原結合断片の治療的有効量
;及び(b)薬学的に許容される担体を含む、癌の予防又は治療用薬学的組成物。 - 前記癌の予防又は治療は、癌治療途中又は癌治療後の癌化学耐性、癌再発、又は癌転移を予防又は治療するものである、請求項13に記載の癌の予防又は治療用薬学的組成物。
- 前記癌は、肺癌、胃癌、卵巣庵、子宮頸部癌、乳癌、膵臓癌、大腸癌、結腸癌、食道癌、皮膚癌、甲状腺癌、腎臓癌、肝癌、頭頚部癌、膀胱癌、前立腺癌、血液癌、多発性骨髓腫、急性骨髓性白血病、悪性リンパ腫、胸腺腫瘍、骨肉腫、繊維性腫瘍及び脳癌からなる群から選択される何れか1つ以上のものである、請求項13に記載の癌の予防又は治療用薬学的組成物。
- 請求項1から4の何れか一項に記載の抗体又はこの抗原結合断片を含む、癌幹細胞成長抑制用組成物。
- 請求項1から4の何れか一項に記載の抗体又はこの抗原結合断片を含む放射線抗癌治療補助用組成物。
- 前記抗体又はこの抗原結合断片は、癌幹細胞を含む癌細胞の放射線に対する敏感度を増進させるものである、請求項17に記載の放射線抗癌治療補助用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0162068 | 2019-12-06 | ||
KR20190162068 | 2019-12-06 | ||
PCT/KR2020/017699 WO2021112640A1 (ko) | 2019-12-06 | 2020-12-04 | 항-tm4sf4 항체 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022521663A true JP2022521663A (ja) | 2022-04-12 |
JP7250938B2 JP7250938B2 (ja) | 2023-04-03 |
Family
ID=76222578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021542571A Active JP7250938B2 (ja) | 2019-12-06 | 2020-12-04 | 抗-tm4sf4抗体及びこの用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230002485A1 (ja) |
EP (1) | EP4071171A4 (ja) |
JP (1) | JP7250938B2 (ja) |
KR (1) | KR102575994B1 (ja) |
CN (1) | CN113227149B (ja) |
WO (1) | WO2021112640A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117597363A (zh) * | 2021-06-18 | 2024-02-23 | 韩国原子力研究院 | 抗-tm4sf4人源化抗体及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537197A (ja) * | 2004-05-11 | 2007-12-20 | ガニュメート・ファーマシューティカルズ・アクチェンゲゼルシャフト | 腫瘍の診断と治療を目的とした表面会合抗原の同定 |
US20110177098A1 (en) * | 2008-07-15 | 2011-07-21 | Lori Sussel | Tm4sf4 and modulators thereof and methods for their use |
JP2014528944A (ja) * | 2011-09-26 | 2014-10-30 | コリア アトミック エナジー リサーチ インスティテュート | 非小細胞肺癌におけるtm4sf4の発現または活性を調節することによって癌細胞の放射線耐性ならびに増殖、転移および浸潤を低減させる方法 |
-
2020
- 2020-12-04 WO PCT/KR2020/017699 patent/WO2021112640A1/ko unknown
- 2020-12-04 KR KR1020200168467A patent/KR102575994B1/ko active IP Right Grant
- 2020-12-04 JP JP2021542571A patent/JP7250938B2/ja active Active
- 2020-12-04 CN CN202080006139.0A patent/CN113227149B/zh active Active
- 2020-12-04 EP EP20897028.5A patent/EP4071171A4/en active Pending
- 2020-12-04 US US17/299,156 patent/US20230002485A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537197A (ja) * | 2004-05-11 | 2007-12-20 | ガニュメート・ファーマシューティカルズ・アクチェンゲゼルシャフト | 腫瘍の診断と治療を目的とした表面会合抗原の同定 |
US20110177098A1 (en) * | 2008-07-15 | 2011-07-21 | Lori Sussel | Tm4sf4 and modulators thereof and methods for their use |
JP2014528944A (ja) * | 2011-09-26 | 2014-10-30 | コリア アトミック エナジー リサーチ インスティテュート | 非小細胞肺癌におけるtm4sf4の発現または活性を調節することによって癌細胞の放射線耐性ならびに増殖、転移および浸潤を低減させる方法 |
Non-Patent Citations (2)
Title |
---|
ACTA BIOCHIM BIOPHYS SIN, vol. Vol.44, Issue 3, JPN7022002965, 2012, pages 224 - 232, ISSN: 0004996346 * |
ONCOTARGET, vol. 5, no. 20, JPN6022026281, 8 September 2014 (2014-09-08), pages 9823 - 9837, ISSN: 0004996345 * |
Also Published As
Publication number | Publication date |
---|---|
US20230002485A1 (en) | 2023-01-05 |
KR102575994B1 (ko) | 2023-09-08 |
CN113227149B (zh) | 2024-05-17 |
CN113227149A (zh) | 2021-08-06 |
EP4071171A4 (en) | 2023-06-28 |
KR20210071856A (ko) | 2021-06-16 |
EP4071171A1 (en) | 2022-10-12 |
JP7250938B2 (ja) | 2023-04-03 |
WO2021112640A1 (ko) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102365972B1 (ko) | 항-pd-1 항체 및 이의 용도 | |
KR102086656B1 (ko) | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 | |
JP5631733B2 (ja) | 抗EpCAM抗体およびその使用 | |
US20120117670A1 (en) | Humanized axl antibodies | |
JP2022509930A (ja) | 抗cd73抗体、その抗原結合フラグメントおよびそれらの使用 | |
SG192816A1 (en) | Novel modulators and methods of use | |
EP1455819A1 (en) | Individualized anti-cancer antibodies | |
JPWO2008044754A1 (ja) | 癌の予防・治療剤 | |
CN113527489B (zh) | 抗cd73的抗体及其用途 | |
AU2021398150A1 (en) | ANTI-SIRPα ANTIBODY AND APPLICATION THEREOF | |
CN110770254A (zh) | 新的抗c-MET抗体及其用途 | |
CN116848135A (zh) | 新颖的抗gremlin1抗体 | |
KR102486507B1 (ko) | 플렉틴-1 결합 항체 및 그의 용도 | |
WO2019179389A1 (en) | Novel anti-egfr antibody polypeptide | |
JP7250938B2 (ja) | 抗-tm4sf4抗体及びこの用途 | |
CN111051513A (zh) | 抗cd147抗体 | |
CN114656566B (zh) | 一种靶向cd47的抗体及其应用 | |
CN112969715B (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
JP2024502670A (ja) | Garpタンパク質抗体及びその適用 | |
CA2456077A1 (en) | Individualized anti-cancer antibodies | |
EP4357363A1 (en) | Anti-tm4sf4 humanized antibody and use thereof | |
KR20240097998A (ko) | 항-tm4sf4 인간화 항체 및 이의 용도 | |
WO2014146487A1 (zh) | 抗细胞表面异位表达的单克隆抗体及其制备方法和用途 | |
WO2024131846A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
CN114380913B (zh) | 一种全人源抗pd-l1抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230322 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7250938 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |